LK-101 is under clinical development by Likang Life Sciences and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData, Phase III drugs for Hepatocellular Carcinoma have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how LK-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LK-101 overview
Cell therapy is under investigation for the treatment of hepatocellular carcinoma, non-small cell lung carcinoma, small-cell lung cancer and solid tumor. The personalized neoantigen based immunotherapy comprises of three courses including immature dendritic cells (DCs), cytokine-induced killer (CIK) cells and cytotoxic T lymphocytes (CTLs). DC, CIK and CTL cells are administered through intra-abdominal cavity, CIK was administered intravenously and administered through parenteral route as injection.
For a complete picture of LK-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.